Research and Development Expenses (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Research and Development Expenses [Abstract] | |||
| Clinical and preclinical trials | $ 4,768 | $ 3,809 | $ 5,104 |
| Salary and related expenses | 909 | 888 | 664 |
| Patents | 229 | 234 | 198 |
| Royalties | 14 | 11 | 11 |
| Laboratory materials | 73 | 63 | 38 |
| Rent | 51 | 51 | 48 |
| Depreciation | 3 | 3 | 4 |
| Others | 28 | 47 | 48 |
| Research and development expense | $ 6,075 | $ 5,106 | $ 6,115 |
| X | ||||||||||
- Definition The amount of expense arising from clinical preclinical trial. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the laboratory material expenses form for its analysis of expenses. No definition available.
|
| X | ||||||||||
- Definition The amount of expense arising from patents. No definition available.
|
| X | ||||||||||
- Definition The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature] Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of expense recognised on rental activities. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense arising from royalties. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense] Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|